指南与共识细菌感染、耐药与抗菌药物

世界卫生组织基本药物目录与AWaRe分类:关于临床感染经验性治疗一线和二线抗生素的建议

WHO's essential medicines and AWaRe: recommendations on first- and second-choice antibiotics for empiric treatment of clinical infections.
指南 / 共识 · Clin Microbiol Infect · 2024-02-09

本文介绍世界卫生组织基本药物目录(EML)自2017年起将抗生素按Access、Watch、Reserve三组分类形成AWaRe分类的历程。2023年AWaRe分类为30多种临床感染提供41种基本抗生素的经验性用药指导,覆盖基层和医院场景,另有257种未列入EML的抗生素也被分配AWaRe组别以支持管理和监测。文章重点阐述指导各感染一线和二线抗生素选择的临床证据基础,旨在优化全球抗生素处方质量、减少不合理使用。

要点

  • 2023年AWaRe分类为30多种临床感染提供41种基本抗生素的经验性用药指导,覆盖基层和医院场景。
  • 另有257种未列入EML的抗生素被分配AWaRe组别,用于管理和监测目的。
  • AWaRe旨在优化全球抗生素处方质量,鼓励在适当情况下使用Access抗生素或不使用抗生素。

核心结论

  • AWaRe分类旨在优化全球抗生素处方质量,通过鼓励在适当情况下使用Access抗生素或不使用抗生素来减少不合理使用。
  • 遵循AWaRe可延长现有抗生素的有效性,同时帮助各国扩大这些救命药物的可及性。

研究设计与样本

  • 本文为世界卫生组织(WHO)基本药物目录(EML)与AWaRe分类的指南性文章,阐述AWaRe的发展历程及指导Access、Watch、Reserve抗生素作为各感染一线和二线选择的临床证据基础。

主要发现

  • 自2017年起,为应对抗菌药物耐药挑战,EML上的抗生素被审查并分为Access、Watch和Reserve三组,形成AWaRe分类。
  • 2023年AWaRe分类为30多种临床感染提供41种基本抗生素的经验性指导,覆盖基层卫生保健和医院设施场景。
  • 另有257种未列入EML的抗生素被分配AWaRe组别,用于管理和监测目的。

关键数值与推荐

  • 2023年AWaRe分类为30多种临床感染提供41种基本抗生素的经验性指导,覆盖基层卫生保健和医院设施场景。
  • 另有257种未列入EML的抗生素被分配AWaRe组别,用于管理和监测目的。

临床怎么用

  • AWaRe旨在促进各国修订国家基本药物目录、更新国家处方指南并监督抗生素使用。
  • AWaRe抗生素手册及相关智能手机应用以该临床证据评估和随后的EML推荐为基础。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The WHO Model List of Essential Medicines (EML) prioritizes medicines that have significant global public health value. The EML can also deliver important messages on appropriate medicine use. Since 2017, in response to the growing challenge of antimicrobial resistance, antibiotics on the EML have been reviewed and categorized into three groups: Access, Watch, and Reserve, leading to a new categorization called AWaRe. These categories were developed taking into account the impact of different antibiotics and classes on antimicrobial resistance and the implications for their appropriate use. The 2023 AWaRe classification provides empirical guidance on 41 essential antibiotics for over 30 clinical infections targeting both the primary health care and hospital facility setting. A further 257 antibiotics not included on the EML have been allocated an AWaRe group for stewardship and monitoring purposes. This article describes the development of AWaRe, focussing on the clinical evidence base that guided the selection of Access, Watch, or Reserve antibiotics as first and second choices for each infection. The overarching objective was to offer a tool for optimizing the quality of global antibiotic prescribing and reduce inappropriate use by encouraging the use of Access antibiotics (or no antibiotics) where appropriate. This clinical evidence evaluation and subsequent EML recommendations are the basis for the AWaRe antibiotic book and related smartphone applications. By providing guidance on antibiotic prioritization, AWaRe aims to facilitate the revision of national lists of essential medicines, update national prescribing guidelines, and supervise antibiotic use. Adherence to AWaRe would extend the effectiveness of current antibiotics while helping countries expand access to these life-saving medicines for the benefit of current and future patients, health professionals, and the environment.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Moja L, Zanichelli V, Mertz D, et al. WHO's essential medicines and AWaRe: recommendations on first- and second-choice antibiotics for empiric treatment of clinical infections. Clin Microbiol Infect. 2024. PMID: 38342438. doi:10.1016/j.cmi.2024.02.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。